HOTH Stock Overview
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Hoth Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.17 |
| 52 Week High | US$4.30 |
| 52 Week Low | US$0.99 |
| Beta | 0.61 |
| 1 Month Change | -23.03% |
| 3 Month Change | -10.00% |
| 1 Year Change | -32.76% |
| 3 Year Change | -96.96% |
| 5 Year Change | -99.15% |
| Change since IPO | -99.45% |
Recent News & Updates
Recent updates
Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury
Sep 20Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule
Jun 29Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation
Nov 12
Hoth Therapeutics extends agreement for experimental antibiotic
Jun 18We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate
Jun 10Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic
May 05Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers
May 03Hoth provides pipeline and regulatory timeline update
Feb 02FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%
Jan 13Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer
Jan 11Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%
Jan 04Hoth therapeutics signs production agreement for HT-001, Shares up 75%
Dec 31Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky
Dec 02
Hoth Therapeutics shows encouraging preclinical action in autoimmune skin disorder
Nov 03Shareholder Returns
| HOTH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -4.9% | 0.9% | 1.2% |
| 1Y | -32.8% | 13.9% | 24.7% |
Return vs Industry: HOTH underperformed the US Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: HOTH underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| HOTH volatility | |
|---|---|
| HOTH Average Weekly Movement | 10.6% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HOTH's share price has been volatile over the past 3 months.
Volatility Over Time: HOTH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 3 | Robb Knie | www.hoththerapeutics.com |
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device.
Hoth Therapeutics, Inc. Fundamentals Summary
| HOTH fundamental statistics | |
|---|---|
| Market cap | US$5.82m |
| Earnings (TTM) | -US$7.85m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs HOTH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOTH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.85m |
| Earnings | -US$7.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.60 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did HOTH perform over the long term?
See historical performance and comparison